# Monoclonal Antibodies: A Promising Weapon Against the Silent Pandemic of Multidrug-Resistant Bacteria

#### Manoj Kumar Jana<sup>1</sup>, Ming-Hsien Chiang <sup>2\*</sup>

1	Department of Biotechnology,	KIIT UNIVERSITY,	Odisha, Indi
---	------------------------------	------------------	--------------

Department of Nutritional Science, College of Human Ecology, Fu Jen Catholic University, New Taipei City, Taiwan. 2

Correspondence: Ming-Hsien Chiang, vincent4811@gmail.com, Tel.: +886-986027808

Abstract: The silent pandemic of antibiotic resistance, exacerbated by the COVID-19 crisis, demands innovative solutions. This re-7 view explores monoclonal antibodies (mAbs) as a promising strategy against multidrug-resistant (MDR) bacterial infections. We 8 examine the evolution of antibacterial mAbs, from early developments to cutting-edge innovations like bispecific antibodies and 9 antibody-antibiotic conjugates. Our analysis of ongoing clinical trials reveals both the potential and challenges of mAb therapies, 10 offering a balanced view of their clinical impact. We discuss emerging concepts such as 'programmable' antibodies and the modula-11 tion of host microbiomes, alongside the synergistic potential of combining mAbs with other novel approaches like bacteriophage 12 therapy. The global health implications of mAb therapies are addressed, exploring their transformative potential in resource-limited 13 settings and innovative production methods to enhance accessibility. We critically examine developmental challenges, regulatory 14 hurdles, and economic considerations, proposing novel frameworks to accelerate progress. Looking ahead, we envision mAbs play-15 ing a crucial role in personalized approaches to infectious diseases, tailoring treatments to individual patient profiles. This review 16 not only summarizes the current landscape but also serves as a catalyst for future research, challenging the scientific community to 17 reimagine the fight against MDR infections. By highlighting both achievements and obstacles, we provide a comprehensive overview 18 of antibacterial mAbs' potential to reshape antimicrobial therapy. This work aims to inspire continued innovation in this critical field, 19 addressing one of the most pressing health challenges of our time. 20

Keywords: antibiotic resistance; vaccine; monoclonal antibody; anti-bacterial infection, COVID-19

The global threat of antimicrobial resistance (AMR) has reached critical levels, presenting an unprecedented chal-23 lenge to public health and economic stability worldwide. (Cassini et al., 2019; CDC, 2019). Recent data paint a stark 24 picture: annually, AMR is responsible for an estimated 1.27 million deaths globally, with projections suggesting this 25 could rise to 10 million by 2050 if current trends persist (O'Neill, 2014). In the United States alone, more than 2.8 million 26 antibiotic-resistant infections occur each year, resulting in over 35,000 deaths (CDC, 2022). The COVID-19 pandemic 27 has further exacerbated this crisis. Despite guidelines recommending against routine antibiotic use for SARS-CoV-2 28 infections, a comprehensive study revealed that nearly 75% of COVID-19 patients received prophylactic antibiotics, 29 even though only 8.6% had confirmed bacterial co-infections (Langford et al., 2021). This widespread misuse of antibi-30 otics has accelerated the development of resistance. Following the peak of the pandemic, the U.S. Centers for Disease 31 Control and Prevention reported a alarming 15% increase in hospital-acquired antimicrobial-resistant infections 32 (Antimicrobial Resistance, 2022). Particularly concerning is the rise in resistant strains of common pathogens, including 33 MRSA, VRE, MDR Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter, which collectively account for 34 a significant proportion of AMR-related deaths. 35

The urgency for effective infection control against antibiotic-resistant bacteria in the current era is a critical concern. 36 As bacterial resistance becomes more prevalent and complex, global awareness of essential infection control measures 37 is expanding, particularly within healthcare settings (Ghoneim et al., 2013). These measures encompass rigorous envi-38 ronmental cleaning, advanced disinfection technologies, stringent hand hygiene practices, and the prudent use of anti-39 biotics to curb further resistance. Additionally, there is a growing emphasis on antimicrobial stewardship programs 40 and the adoption of rapid diagnostic technologies to guide appropriate antibiotic utilization (Frost et al., 2023). Despite 41 concerted efforts, the period from 2020 to 2023 witnessed a disappointingly low number of new antibiotic approvals, 42 with only a few novel compounds entering the market (Butler et al., 2023). Alarmingly, the pace of drug resistance 43 development continues to outstrip that of new drug discoveries significantly, leading to a widening gap in our antimi-44 crobial arsenal (Batchelder et al., 2023). This trend is particularly worrisome with the emergence of pan-resistant bacte-45 rial strains that are impervious to all existing antibiotics (Kim et al., 2023a). The challenge is further exacerbated by the 46

2

1

4

5

6

3

economic realities of antibiotic development, with many pharmaceutical companies scaling back or discontinuing their 47 antibiotic research programs due to low returns on investment, resulting in an innovation gap in this crucial area (Kim, 48 et al., 2023a). Given this challenging scenario, it is imperative to explore innovative approaches beyond traditional an-49 tibiotics to combat bacterial infections. Promising alternative strategies include the development of immunotherapies 50 like vaccines and monoclonal antibodies (mAbs) targeted at combating multidrug-resistant (MDR) bacteria (McCulloch 51 et al., 2022; Seixas et al., 2022). These approaches offer several advantages over traditional antibiotics, including high 52 specificity, potentially lower risk of resistance development, and the ability to leverage the host immune system's power 53 (Elemam et al., 2021). Furthermore, recent advancements in biotechnology, such as artificial intelligence (AI)-driven 54 antibody design and novel antibody engineering techniques, have unlocked new possibilities in this domain. By lever-55 aging AI technologies, researchers have been able to accelerate the discovery of antibodies through the design of tar-56 geted libraries enriched for specific binding properties, thereby reducing the need for extensive experimental screening 57 (Chungyoun and Gray, 2023). 58

#### **Challenges in Developing Vaccines for Bacterial Infections**

From the development of human medicines to the recent battles with COVID-19, vaccines have consistently proven 60 to be among the most cost-effective methods for preventing infectious diseases, even in immunocompromised groups 61 (Antinori and Bausch-Jurken, 2023). Research has particularly highlighted the cost-effectiveness of vaccinating against 62 MDR bacteria, especially in children under five and in lower-middle-income to low-income countries where the disease 63 burden is notably high (Anderson et al., 2023; Lee et al., 2023). For instance, a study in the US found that the pneumo-64 coccal conjugate vaccine (PCV13) halved the rates of antibiotic-resistant invasive pneumococcal diseases across all age 65 groups, from 61% to 27% (Bajema et al., 2022). Additionally, typhoid conjugate vaccines (TCV) have shown substantial 66 efficacy in curbing the spread of Salmonella typhi in impoverished regions. The WHO has systematically validated the 67 effectiveness of TCV in controlling typhoid fever in endemic areas and supports its integration into routine vaccination 68 programs in high-risk countries (Saha et al., 2021). As antibiotics continue to lose their effectiveness, the urgency to 69 develop new therapeutic strategies to tackle evolving MDR bacterial strains is more pressing than ever (Stokes et al., 70 2019). The focus on vaccines has shifted from theoretical discussions to active investigations of their practicality in clin-71 ical settings (Jansen et al., 2018; Buchy et al., 2020). Vaccination could be a strategic response to antibiotic resistance, 72 particularly if it significantly reduces antibiotic use in high-consumption subpopulations (Davies et al., 2021). Never-73 theless, the development of vaccines for MDR bacteria faces three significant challenges: technical complexities, identi-74 fication of target groups, and economic feasibility (López-Siles et al., 2020). 75

Initially, the technical challenge involves identifying an appropriate vaccine candidate by leveraging previous 76 methodologies that use virulence factors, surface sugar molecules, capsules, or outer membrane proteins as antigens. 77 This is followed by the utilization of bioinformatics to screen for proteins that exhibit potential as epitopes, focusing 78 particularly on those that are surface-exposed and highly conserved. Moreover, translating results from animal models 79 to human clinical trials presents significant hurdles due to variations in cytokine expression levels and differences in 80 immunological responses between humans and rodents (Mak et al., 2014). After these extensive and resource-intensive 81 verification steps, only a handful of candidates emerge as successful (Chiang et al., 2015; Michalik et al., 2016). 82

Identifying the primary target groups for vaccination is crucial. Currently, vaccinations are primarily directed towards high-risk individuals, including patients in intensive care units, those with chronic conditions, ventilator users, cancer patients, and those undergoing surgery. However, the effectiveness of preoperative vaccinations or those administered at the onset of disease is limited. Defining high-risk groups in practical terms remains a challenge, which may hinder broader vaccine promotion and utilization. 87

The market for vaccines against MDR bacteria is relatively small. According to the U.S. Centers for Disease Control 88 and Prevention, around 2.8 million patients contract MDR bacterial infections annually (CDC, 2019). Although this 89 figure is substantial, the incidence rate of these infections is lower compared to other diseases, yet they present higher 90 mortality rates. Furthermore, MDR bacterial infections associated with healthcare settings significantly increase costs 91 due to extended stays in intensive care units and prolonged hospital admissions (Pasero et al., 2021). Despite the poten-92 tial impact, the economic incentives for biopharmaceutical companies are limited. The substantial investment required 93 for research and development, coupled with short profit margins and product lifespans, renders this sector less appeal-94 ing compared to more lucrative areas such as cancer treatment. 95

In light of the ongoing challenge posed by MDR bacterial infections and the relentless development of new antibiotics struggling to keep pace with drug resistance, exploring alternative treatment approaches becomes crucial. One such promising method is the development of therapeutic mAbs, which may offer a more viable strategy (McConnell, 2019; López-Siles, et al., 2020). Unlike vaccines, which typically require several weeks to elicit protective immunity, 99

mAbs can provide immediate protection upon administration. This review aims to deliver a comprehensive examination of the role of mAbs in combating MDR bacterial infections. It will cover the mechanisms through which mAbs function, delve into ongoing research and clinical trials, and discuss the challenges and limitations that accompany mAb treatments. Additionally, this review will provide a comparative analysis of mAbs against other treatments for MDR infections, addressing the regulatory and ethical considerations involved in their use. Ultimately, the goal is to furnish usights into the future possibilities of mAb therapies in the realm of MDR bacterial infections, thereby informing and guiding further research and development efforts in this pivotal area.

#### Advancements in the Development of Antibacterial Monoclonal Antibodies

MAbs are homogeneous antibodies produced from a single B-cell clone, each capable of targeting a specific epitope 108 on an antigen. Historically, despite the availability of numerous antibiotics, the cost of utilizing mAbs as a treatment 109 option was prohibitively high, leading to slower development in this field compared to cancer and autoimmune dis-110 eases (Monserrat-Martinez et al., 2019; Lu et al., 2020). Today, propelled by advancements in precision medicine and 111 biotechnology, the demand for mAbs in anti-infective clinical applications is increasing. To appreciate the potential of 112 mAbs, it's important to understand the diverse roles of immunoglobulin isotypes in the immune response. Immuno-113 globulins, also known as antibodies, are proteins produced by B cells that play a crucial role in defending the body 114 against pathogens. There are five major isotypes of immunoglobulins (IgD, IgE, IgM, IgA, IgG), each with distinct func-115 tions and distributions within the body (Fig. 1). 116

		¥	*	<u>}{</u>					_
Functional activity	lgD	lgE	lgM	lgA	lgG1	lgG2	lgG3	lgG4	
Neutralization			+	++	++	++	++	++	Does not apply
Opsonization			+	+	+++		++	+	+ Applies
Sensitization for killing by NK cells					++		++		++ Strongly applies
Sensitization of mast cells		+++			+		+		+++ Heavily applies
Activates complement system			+++	+	++	+	+++		

#### Figure 1. Functional activities of different immunoglobulin isotypes.

The table summarizes the key functions of the five major antibody isotypes (IgD, IgE, IgM, IgA, IgG) and the four subclasses of 119 IgG (IgG1, IgG2, IgG3, IgG4) in the immune response. These functions include neutralization of pathogens, opsonization (facilitating 120 phagocytosis), activation of natural killer (NK) cells, sensitization of mast cells (leading to degranulation and release of inflammatory 121 mediators), and activation of the complement system (a cascade of proteins that help clear pathogens). The number of "+" symbols 122 indicates the relative strength of each isotype's activity in a particular function, with "+++" being the highest. The "-" symbol indicates 123 that the isotype does not perform that function. 124


MAbs are primarily categorized into four types based on their origin: mouse-derived, human-mouse chimeric, 126 humanized, and fully human mAbs (Maynard, 2021) (Fig. 2). Mouse-derived mAbs, the first generation of mAb technology, are hybridomas created by fusing B lymphocytes from immunized mice with mouse myeloma cells, widely 128 used in foundational antibody research. Human-mouse chimeric mAbs result from the genetic recombination of the mouse antibody's variable region (Fv) gene with the constant region (Fc) of the human antibody, retaining about 30% 130

107

117

118

of murine antibody characteristics (Hwang and Foote, 2005). Humanized mAbs are crafted by replacing murine mAb 131 complementarity-determining regions (CDRs) with those in human antibodies, achieving approximately 90% humani-132 zation (Harding et al., 2010), thus maintaining the specificity of murine mAbs while being more compatible with human 133 systems. Fully human mAbs, considered the optimal choice for therapy, are produced using techniques such as phage 134 antibody library expression, ribosome display, and transgenic mouse technology (Klemm et al., 2021). These mAbs 135 completely eliminate interspecies heterogeneity, reducing the risk of human anti-chimeric antibody (HACA) reactions 136 (Hwang and Foote, 2005; Kang and Seong, 2020). 137



the first mAb

#### Figure 2. Progression of monoclonal antibody development

This figure illustrates the progression of mAb technology over time, focusing on the reduction of immunogenicity. (A) Bar graph 140 showing the relative immunogenicity of four mAb generations: murine, chimeric, humanized, and fully human. The decreasing 141 height of bars represents reduced immune system reactivity. (B) Timeline of mAb development, displaying three key attributes for 142 each generation: (i) generic nomenclature, (ii) percentage of murine components, and (iii) year of first identification. The gradual 143 decrease in murine content correlates with improved clinical applicability. CDRs: complementarity-determining regions. This figure 144 demonstrates how antibody engineering has advanced to produce mAbs with enhanced therapeutic potential and reduced risk of 145 adverse immune responses. 146

Compared to traditional antibiotics, mAbs offer several distinct advantages for treating bacterial infections: (1) 148High specificity, effectively targeting MDR bacteria without affecting normal intestinal flora (Wang-Lin and Balthasar, 149 2018); (2) A strong safety profile; (3) The potential to be used in conjunction with standard antibiotics as antibody-drug 150 conjugates, which can reduce dosage requirements and minimize selective pressure (Mariathasan and Tan, 2017); (4) 151 Enhanced affinity and safety through genetic modifications, such as the development of single-chain fragment variable 152 (scFv) antibodies and fully human antibodies (Hwang and Foote, 2005; Kang and Seong, 2020); (5) Extended half-life, 153 ensuring sustained bioavailability and offering benefits in dosing compliance and adherence (Wang-Lin and Balthasar, 154 2018); (6) Vital therapeutic benefits for immunocompromised patients or those unsuitable for vaccination (Motley et al., 155 2019); (7) Environmentally friendly production processes that use minimal chemical agents (Pietrzykowski et al., 2013) 156 ; (8) Absence of environmental accumulation, unlike antibiotics; (9) Lower likelihood of developing drug resistance, 157 due to targeting specific virulence factors rather than essential survival proteins (Szijártó et al., 2018). In addition, mAbs 158 are currently being explored in several clinical trials as potential adjuncts to antibiotic therapy, showing promise in 159 enhancing treatment outcomes while aiming to reduce or replace the use of antibiotics (Zhou et al., 2016; Mariathasan 160 and Tan, 2017; Cavaco et al., 2022). 161

Despite their advantages, all mAbs are recognized as foreign by the recipient's immune system, which can lead to 162 the production of neutralizing antibodies or pathological immune responses. Chimeric mAbs inherently contain murine 163 elements that may induce HACA responses. Similarly, humanized and fully human mAbs might trigger anti-drug 164

138

139

antibody reactions, potentially impacting their pharmacokinetics (PK) and therapeutic efficacy (Wang-Lin and 165 Balthasar, 2018).

# **Ongoing Research and Clinical Investigations**

The landscape of antibacterial mAb development is rapidly evolving, with numerous clinical trials underway (Medicine, 2023). A comprehensive analysis of data from ClinicalTrials.gov reveals a diverse array of targets and approaches for these novel therapeutics (Table 1). The ongoing clinical trials can be categorized based on target pathogens and mechanisms of action: 170

- Staphylococcus aureus-targeted mAbs: Several mAbs are in development against S. aureus, targeting 172 various virulence factors. Tefibazumab, a humanized mAb, targets clumping factor A, while 514G3 173 targets the cell wall moiety Protein A. MEDI4893 (suvratoxumab) and AR-301 (tosatoxumab) both 174 target alpha-hemolysin, a key virulence factor. ASN-100, a combination of two human mAbs, targets 175 multiple toxins including alpha-hemolysin and leucocidins (Yang et al., 2016). The multifaceted strat-176 egies involving different mAbs targeting various toxins and proteins of S. aureus underscore the com-177 plexity of S. aureus pathogenicity and the necessity for diverse therapeutic interventions (Raafat et al., 178 2019). 179
- Pseudomonas aeruginosa-targeted mAbs: P. aeruginosa, a significant cause of hospital-acquired infections, is the target of several mAbs in development. KB001 and MEDI3902 target the type III secretion
  181 system protein PcrV (Warrener et al., 2014), has shown promise in preclinical studies, with some antibodies proving to be safe and well-tolerated. AR-105 (Aerucin) targets alginate, while KBPA-101
  183 (Aermab) targets the O-antigen of lipopolysaccharide. Interestingly, PsAer-IgY, derived from chicken
  184 egg yolk, targets flagellin, showcasing the diversity of antibody sources being explored (Frank et al., 2002).
- *Clostridium difficile*-targeted mAbs: Building on the success of bezlotoxumab, other mAbs targeting C. *difficile* toxins are in development. MK-3415A combines antibodies against both toxin A and B, while
  GS-CDA1/MDX-1388 targets toxin A and a fragment of toxin B (Wilcox et al., 2017). Furthermore,
  the mechanism of action and epitopes of bezlotoxumab, a neutralizing antibody targeting *C. difficile*toxin B, have been elucidated through X-ray crystallography, providing insights into how this antibody
  neutralizes the toxin (Orth et al., 2014). These antibodies offer targeted strategies to neutralize the
  virulence factors produced by *C. difficile*, potentially reducing the recurrence and severity of CDI.
- Bioterrorism defense: *Bacillus anthracis* toxins consist of three proteins: protective antigen (PA), lethal
  factor (LF), and edema factor (EF), which interact in a binary fashion to produce edema toxin (PA plus
  EF) and lethal toxin (PA plus LF; LeTx). Raxibacumab, obiltoxaximab, and other mAbs targeting the
  PA component of *Bacillus anthracis* toxin represent critical advancements in biodefense (Little et al.,
  2011). These mAbs are approved to treat inhalation anthrax and have received significant attention
  due to their potential role in counter-bioterrorism measures.
- Broad-spectrum approaches: Some mAbs in development aim for broader applicability. F598, for instance, 200 targets poly-N-acetylglucosamine (PNAG), a surface polysaccharide found in multiple bacterial 201

species (Soliman et al., 2020). This approach could potentially lead to therapies effective against a wide range of pathogens. 203

Novel targets and approaches: The clinical trials also reveal exploration of novel targets. For example,204TRL1068 and CMTX-101 target biofilm scaffolding proteins, addressing the challenging issue of bio-205film-associated infections (Ryser et al., 2019). XJ103, targeting α-isopropylmalate dehydrogenase in206Streptococcus pneumoniae, represents an innovative approach to pneumococcal infections.207

These diverse approaches in mAb development reflect the complexity of bacterial pathogenesis and the 208 need for multi-faceted strategies to combat antibiotic resistance. By targeting specific virulence factors, toxins, 209 and conserved surface structures, these mAbs aim to neutralize bacterial pathogenicity without directly killing 210 the bacteria, potentially reducing the selective pressure that leads to antibiotic resistance. The success of bezlo-211 toxumab (Zinplava) against C. difficile infections serves as a proof of concept, demonstrating the clinical 212 viability of mAb-based therapies for bacterial infections. Approved by the FDA in 2016, this human IgG1 213 antibody effectively reduces recurrent infections in high-risk patients, particularly those on antibiotic regimens 214 or with compromised gastrointestinal health (Wilcox, et al., 2017). 215

Moreover, some mAbs show promise in addressing antibiotic resistance through novel mechanisms. For 216 instance, antibodies targeting the type 3 secretion system in P. aeruginosa or outer membrane proteins in 217 Acinetobacter baumannii and Salmonella species may help restore antibiotic sensitivity. A groundbreaking 218 study by Huang et al. (2019) demonstrated that antibodies against A. baumannii outer membrane vesicles 219 could significantly enhance the efficacy of levofloxacin and ciprofloxacin against multidrug-resistant strains, 220 both in vitro and in vivo (Huang et al., 2019). As research progresses, the potential applications of mAbs in 221 infectious disease management continue to expand. The diversity of targets and mechanisms represented in 222 ongoing clinical trials highlights the versatility of this therapeutic approach. From species-specific interven-223 tions to broad-spectrum strategies, and from toxin neutralization to biofilm disruption, mAbs offer a promising 224 arsenal in the fight against antibiotic-resistant infections. 225

Agents	Bacterial Species	Target	Sponsor	Phase	NCT no.	Immunogenicity
Tefibazumab	Staphylococcus aureus	clumping factor A	Bristol-Myers Squibb	п	NCT00198289	Humanized
514G3		cell wall moiety Protein A (SpA)	XBiotech	п	NCT02357966	Human (isolated and cloned from a healthy human donor)
MEDI4893 (Suvratoxumab)		alpha-hemolysin	Medimmune	п	NCT02296320	Human (VelocImmune mice)
ASN-100 (ASN- 1 and ASN-2)		alpha-hemolysin, gamma-hemolysin, bicomponent leucocidin (HlgAB, HlgCB, LukED, LukSF, and LukGH)	Arsansis	п	NCT02940626	Human

Table 1. The ongoing clinical trials for anti-bacterial mAbs are accessible on ClinicalTrials.gov (accessed on 1 June 2024).

AR-301 (Tosatoxumab)		alpha toxin	Aridis Pharmaceuticals	III	NCT03816956	Human (convalescent patient B-cell)
DSTA-4637S		Teichoic Acid (Antibody- Antibiotic Conjugate)	Genentech and Roche	Ι	NCT03162250	Human
Aurograb <sup>®</sup>		ABC transporter GrfA	NeuTec Pharma / Novartis	III	NCT00217841	scFv
KB001		type III secretion system, PcrV	KaloBios	П	NCT00638365	humanized PEGylated Fab
PsAer-IgY		surface protein (Flagellin)	Mukoviszidose Institut gGmbH	III	NCT01455675	Chicken egg yolk
AR-105 (Aerucin)	Pseudomonas aeruginosa	alginate	Aridis Pharmaceuticals	П	NCT03027609	Human
KBPA-101 (Aermab)		LPS O-antigen (serotype O11)	Aridis (Kenta Biotech)	Ш	NCT00851435	Human
MEDI3902		type III secretion system, PcrV, exopolysaccharide, Psl	Medimmune	П	NCT02696902	Human (bispecific phage display and VelocImmmune mouse)
MK-3415A (actoxumab- bezlotoxumab)		toxin A/B	Merck Sharp & Dohme	Ш	NCT01513239	Human
Bezlotoxumab (Zinplava®)	Clostridium difficile	toxin B	Merck Sharp & Dohme	IV	NCT03880539	Human
GS-CDA1/ MDX-1388		toxin A/ C-terminal toxin B fragment	MassBiologics/ Merck	П	NCT00350298	human
Raxibacumab (ABthrax®/Anth rin®)		protective antigen (PA) component of anthrax toxin	Human Genome Sciences	IV	NCT02177721	Human (phage display)
Obiltoxaximab (Anthim <sup>®</sup> , ETI- 204)	Bacillus	PA component of anthrax toxin	Elusys Therapeutics	IV	NCT03088111	Human-mouse (hybridoma)
MDX-1303 (Valortim®)	anthracis	Uncleaved and cleaved PA	PharmAthene	Ι	NCT00964561	Human
AVP-21D9 (ThravixaTM)		PA component of anthrax toxin	Emergent BioSolutions	I	NCT01202695	Human
NTM-1632/3	Clostridium botulinum	botulinum neurotoxin type B	NIAID	Ι	NCT02779140	Humanized

XOMA 3ab		botulinum neurotoxin type B	XOMA/NIAID	Ι	NCT01357213	Humanized
A82 / B86	Clostridium Tetanus	anti-tetanus toxin	Changchun BCHT Biotechnology Co.	Ι	NCT06360250	Human
TRL1068	Biofilm— multiple species	biofilm scaffolding	Trellis Bioscience	Ι	NCT04763759	Human
CMTX-101		proteins DNABII	Clarametyx Biosciences, Inc.	Ι	NCT05629741	Human
F598	Multiple species	Poly-N- acetylglucosamine (PNAG)	Alopexx Pharmaceuticals	П	NCT03222401	Human
Pagibaximab (BSYX-A110)	Staphylococcal Sepsis	lipoteichoic acid	Biosynexus	III	NCT00646399	Humanized
XJ103	Streptococcus pneumoniae	α-isopropylmalate dehydrogenase	Starmab biologics Co,.ltd	Ι	NCT06026748	humanized
caStx1/caStx2	Shiga Toxin- Producing <i>E.</i> <i>coli</i>	shiga toxins	Thallion Pharmaceuticals	П	NCT01252199	Humanized

#### Mechanisms of Action: How Monoclonal Antibodies Combat MDR Bacteria

mAbs offer a multifaceted approach to combating MDR bacteria, targeting conserved surface antigens such as 229 lipopolysaccharide (LPS), capsular polysaccharides, and outer membrane proteins. This specificity allows mAbs to recognize and attach to bacterial cells effectively, even in antibiotic-resistant strains (Seixas, et al., 2022). Figure 3 illustrates 231 the diverse mechanisms by which mAbs combat MDR bacteria: 232


Neutralizing bacterial toxins and virulence factors (Fig. 3A): mAbs can bind to and neutralize toxins produced by 233 bacteria, preventing them from damaging host cells. For instance, bezlotoxumab, an mAb developed to target Clostrid-234 ioides difficile toxin B, has shown efficacy in reducing the recurrence of C. difficile infections (Zurawski and McLendon, 235 2020b). The figure shows mAbs neutralizing and inhibiting toxins before they can interact with the bacterial cell surface. 236 Blocking receptor binding (Fig. 3B): mAbs can interfere with bacterial adhesion to host cells by binding to bacterial 237 adhesins or host cell receptors. This mechanism prevents the initial attachment of bacteria to host tissues, a critical step 238 in infection. Antibody-Drug Conjugates (ADCs) (Fig. 3C): This innovative approach combines the specificity of mAbs 239 with the potency of antibiotics. ADCs allow for targeted delivery of antibiotics to bacterial cells, potentially increasing 240 efficacy while reducing systemic exposure and side effects. Inhibition/disruption of biofilm formation (Fig. 3D): mAbs 241 can target key bacterial surface structures involved in biofilm formation, a critical virulence factor for many MDR path-242 ogens. For example, an mAb targeting the Psl exopolysaccharide of Pseudomonas aeruginosa has been shown to disrupt 243 biofilm formation and restrict bacterial invasion in a mouse model of pneumonia (Zurawski and McLendon, 2020b). 244 NETosis and opsonophagocytosis (Fig. 3E): By coating the bacterial surface, mAbs mark bacteria for phagocytosis (op-245 sonization) and destruction by immune cells. This process enhances the host's natural immune response against the 246 pathogen (Vacca et al., 2022). Additionally, mAbs can induce NETosis, where neutrophils release extracellular traps to 247 capture and kill bacteria. Complement-dependent cytotoxicity (Fig. 3F): mAb binding can activate the complement sys-248 tem, leading to direct bacterial killing via membrane attack complexes (Zurawski and McLendon, 2020b). The figure 249 illustrates how complement proteins (C1q) bind to antibodies on the bacterial surface, leading to phagocytosis and lysis. 250 Antibody-dependent cell-mediated cytotoxicity (ADCC) (Fig. 3G): This mechanism involves the recruitment of immune 251 effector cells, such as natural killer (NK) cells and cytotoxic T cells, to destroy antibody-coated bacteria. The figure 252

227

259


shows how NK cells and CD8+ T cells interact with antibody-coated infected cells, releasing cytotoxic granules to kill 253 the target. 254

The ability of mAbs to employ these diverse mechanisms makes them particularly effective against MDR strains, 255 as the targeted antigens are often essential for bacterial virulence and survival (Vacca, et al., 2022). By disrupting multiple aspects of bacterial pathogenesis, from toxin neutralization to biofilm disruption and immune system activation, 257 mAbs offer a comprehensive approach to combating antibiotic-resistant infections. 258



E. NETosis/ F. Complementopsonophagocytosis dependent cytotoxicity

#### G. Antibody-dependent cell-mediated cytotoxicity (ADCC)



# Figure 3. Mechanisms of mAb in combating bacterial infections.

This figure illustrates the intricate mechanisms through which mAbs combat bacterial infections. A. Neutralization of Bacterial 262 Virulence Factors: mAbs neutralize or inhibit bacterial virulence factors, mitigating their pathogenic effects. B. Blocking Bacterial 263 Adhesion: mAbs block receptor-mediated adhesion, preventing bacteria from attaching to host cells and hindering infection progres-264 sion. C. ADC Strategy: mAbs conjugated with antibiotics enhance the precision and effectiveness of targeting and eliminating bacte-265 ria. D. Disruption of Biofilm Formation: mAbs inhibit or disrupt biofilm formation, a primary bacterial defense mechanism, thereby 266 facilitating bacterial clearance. E. mAb-Mediated NETosis/Opsonophagocytosis: mAbs promote bacterial clearance by facilitating 267 neutrophil extracellular traps (NETs) and enhancing phagocytosis. F. Complement-Dependent Cytotoxicity: mAbs activate comple-268 ment-dependent cytotoxicity, leading to the lysis of bacterial cells. G. Synergy Between Innate and Adaptive Immunity: mAbs en-269 hance the synergy between innate and adaptive immune responses in ADCC, promoting the clearance of bacterial infections (Lehar 270 et al., 2015; Zurawski and McLendon, 2020a; Cavaco, et al., 2022; Wang et al., 2022). 271

260

Recent advancements in mAb development have ushered in a new era of multivalent and combinatorial strategies. 273 This shift towards more complex antibody designs aims to neutralize antigens more extensively, closely mimicking the 274 human natural immune system's polyclonal response (Gilchuk et al., 2020; Yadav et al., 2021). A groundbreaking study 275 by Buckley et al. (Buckley et al., 2023) exemplifies this approach, introducing an engineered multivalent protein biologic 276 agent that targets five surface proteins and neutralizes five different S. aureus virulence factors simultaneously. This 277 innovative construct is designed to resist proteolysis, avoid Fc binding to S. aureus IgG-binding proteins, and neutralize 278 toxins. It features tandem centyrin moieties, small protein scaffolds derived from the fibronectin type III-binding do-279 main, that bind to and neutralize two S. aureus leukocidins, thereby protecting phagocytes and enhancing their antimi-280 crobial function. The development of multivalent mAbs has been further enhanced by collecting antibodies from mul-281 tiple B-cell lineages, resulting in varying site affinities for the same pathogen. This diversity in binding profiles offers a 282 broader range of neutralization options and significantly reduces the likelihood of pathogens developing escape muta-283 tions, thus inhibiting or slowing down the emergence of MDR bacteria (Kennedy and Read, 2017). The presence of 284 multiple epitope binding sites in these advanced mAbs allows them to bind to numerous antigenic sites, potentially 285 compensating for the gaps left by antibiotics and vaccines after treatment failure (Batchelder, et al., 2023). This approach 286 is particularly promising for addressing chronic or recurrent infections that often result from incomplete clearance by 287 standard therapies. 288

The integration of these multivalent mAb strategies with existing antibiotic regimens presents a powerful multi-289 pronged approach to combating bacterial infections. This combined use of mAbs with antibiotic therapy builds evolu-290 tionary barriers against bacteria, reducing the likelihood of treatment failure due to the development of drug-resistant 291 strains (Zurawski and McLendon, 2020b; Zurawski and McLendon, 2020a). The synergistic effect of this approach offers 292 several benefits, including reduced antibiotic usage, enhanced bacterial clearance, and immunomodulation. As research 293 in this field progresses, these advanced mAb strategies hold the promise of ushering in a new era of targeted, efficient, 294 and resistance-proof therapies for bacterial infections, potentially revolutionizing our approach to combating the global 295 challenge of antimicrobial resistance. 296

# Novel Monoclonal Antibody Formats in Combatting Bacterial Infection

Several novel mAb formats have gained significant attention in recent years, including antibody-drug conjugates, 298 bispecific mAbs, IgY, nanobodies, and single-chain variable fragments (scFv) (Table 2). 299

- Antibody-Drug Conjugates: These involve drugs or toxins covalently attached to immunoglobulins, allowing
   for targeted delivery to specific sites. This technique shows great promise for killing cancer cells or microbes
   (Tvilum et al., 2023).
- Bispecific mAbs: These combine two distinct mAbs to simultaneously target two different proteins, enabling multiple physiological or anti-tumor responses by engaging two antigens or epitopes at once (DiGiandomenico de t al., 2014b).
- c. IgY: This is an immunoglobulin found in birds and reptiles, showing potential applications in treating P. aeruginosa and S. aureus infections (Amro et al., 2018) (Zhen et al., 2008; Thomsen et al., 2016a).
   307
- d. These are single-domain antigen-binding fragments derived from camelid heavy-chain antibodies, offering advantages such as small size, high stability, and ease of production (Salvador et al., 2019).
   309
- e. Single-Chain Variable Fragments (scFv): These are fusion proteins of the variable regions of the heavy and light chains of immunoglobulins, while single-domain antibodies (sdAb) consist of either a light chain or heavy chain variable region (Satheeshkumar, 2020). scFv molecules have shown promise in treating neovascular age-related macular degeneration (Tadayoni et al., 2021).
   310

Each of these novel mAb types possesses unique characteristics and advantages. Antibody-drug conjugates are particularly effective in targeting and delivering cytotoxic agents to cancer cells or pathogens. Bispecific mAbs can elicit multiple immune responses by targeting two different antigens simultaneously. IgY antibodies hold potential for specific bacterial infections. Nanobodies, due to their small size and high stability (enhancements like PEGylation or fusion with albumin-binding domains can extend its circulation time), are advantageous for various applications. scFv molecules are being explored for their efficacy in treating complex conditions like neovascular age-related macular degenand advantageous for various age-related macular degensuch age-related macular degens

Novel m	nAbs Types	Characteristics	Example	Advantages	Disadvantages	Ref.
Antibody-Drug conjugation		Delivering drugs directly to specific antigens.	DSTA4637A / MRSA / Human IgG1- dmDNA31	<ol> <li>Potentially minimizes the side effects associated with antibiotics.</li> <li>Remains stable in circulation.</li> <li>Revives antibiotics that exhibit poor pharmacokinetic properties or cause undesired host toxicity.</li> </ol>	<ol> <li>The effectiveness is         <ul> <li>limited by the abundance</li> <li>of antigens on bacterial</li> <li>cell surfaces.</li> </ul> </li> <li>Comprises various         <ul> <li>components with distinct</li> <li>chemical characteristics.</li> </ul> </li> <li>Presents challenges in         <ul> <li>manufacturing.</li> </ul> </li> </ol>	(Mariatha an and Tan, 2017 (Cavaco, e al., 2022)
Bispecific mAbs		Simultaneously binds to two different epitopes using a mAb.	MED13902 / P. aeruginosa PcrV & Psl	<ol> <li>Alternative therapeutic approach, substituting combination therapy with two monospecific drugs.</li> <li>Sensitive immunoassays enable swift and straightforward detection of infectious diseases.</li> </ol>	<ol> <li>Production by two separate cell lines makes it costly and challenging to harvest.</li> <li>Potential for decreased stability or susceptibility to aggregation.</li> </ol>	(DiGiando menico et al., 2014a) (Nyakatur et al., 2017 (Sedykh e al., 2018)
IgY		Highly conserved to human IgG.	PsAer-IgY / P. <i>aeruginosa</i> surface protein (Flagellin)	<ol> <li>Low-cost and minimal production effort.</li> <li>Rapid production is feasible for acute illnesses.</li> <li>Lower background of cross- reactivity.</li> </ol>	<ol> <li>Possibility of host- produced anti-IgY antibodies</li> <li>Unable to activate human Fc receptors and the complement system.</li> </ol>	(Thomser et al., 2016b) (Lee et al. 2021)
Nanobody	2.5 nm	Antibody lack of light chain and constant domain.	NbD7 / Ehrlichia chaffeensis translocated factor-1	<ol> <li>Recesses or concealed epitopes inaccessible to traditional mAbs.</li> <li>Exhibits remarkable stability, hydrophilicity, and solubility, contributing to sustained binding capacity.</li> <li>Diverse expression systems.</li> </ol>	<ol> <li>High uptake in kidney.</li> <li>Risk of immunogenicity.</li> </ol>	(Salvador et al., 2015 (Mei et al. 2022)
scFv		An antibody comprises only the variable regions of the heavy and light chains.	Brolucizumab / Neovascular Age- related Macular Degeneration VEGF- A	<ol> <li>Preserves the original antibody's binding affinity and specificity.</li> <li>Easily constructed, expressed, and manufactured in large quantities.</li> </ol>	<ol> <li>Limited half-life and low stability in circulation.</li> <li>Requires high doses and continuous administration.</li> </ol>	(Ahmad e al., 2012) (Tadayon et al., 2022 (Muñoz- López et al., 2022)

# Table 2. The novel types of mAbs.

While novel mAb types offer promising avenues for combating MDR bacteria, each variant comes with its own set 322 of challenges that researchers must address. ADCs, despite their potential for targeted drug delivery, face hurdles in 323 maintaining drug stability and minimizing off-target effects, which can lead to unintended toxicity in healthy tissues 324 (Kim and Kim, 2015). The complex architecture of bispecific mAbs, while allowing for dual-targeting capabilities, pre-325 sents significant manufacturing difficulties, often resulting in low yields and high production costs (DiGiandomenico, 326 et al., 2014b). IgY antibodies, derived from avian sources, show promise in their broad-spectrum activity, but concerns 327 persist regarding their potential immunogenicity in humans and the complexity of their purification process (Amro, et 328 al., 2018). Nanobodies, despite their small size and stability, may struggle with limited tissue penetration, potentially 329 reducing their efficacy against deep-seated infections. Additionally, their non-human origin could trigger immune re-330 sponses in patients, necessitating careful humanization strategies (Salvador, et al., 2019). Single-chain variable frag-331 ments (scFv), while offering enhanced tissue penetration due to their small size, are prone to aggregation and exhibit 332 significantly shorter half-lives compared to full-length antibodies, potentially requiring more frequent dosing to main-333 tain therapeutic levels (Satheeshkumar, 2020). Despite these challenges, the unique properties of these novel mAb types 334 present distinct opportunities for therapeutic interventions against MDR bacteria. ADCs, for instance, could revolution-335 ize the delivery of antimicrobial agents directly to pathogens, potentially reducing systemic toxicity. Bispecific mAbs 336 offer the possibility of simultaneously targeting multiple bacterial epitopes or engaging both the pathogen and the host 337 immune system, potentially enhancing clearance of resistant strains. IgY antibodies, with their evolutionary distance 338 from mammalian antibodies, might provide novel binding sites for conserved bacterial targets that have evaded tradi-339 tional mAb approaches. Nanobodies, with their exceptional stability and ability to recognize unique epitopes, could 340 prove valuable in developing new diagnostic tools or as building blocks for more complex antibody constructs. scFv 341 molecules, despite their limitations, offer potential in phage display technologies for rapid selection of high-affinity 342 binders against emerging pathogens. As we navigate the post-COVID era, where the threat of MDR bacteria looms 343 larger than ever, continued research and development efforts are crucial to fully harness the potential of these novel 344 mAb types. By addressing their respective drawbacks and leveraging their unique advantages, we may uncover inno-345 vative solutions to combat antibiotic resistance and develop more effective therapies against bacterial infections. 346

# Synergizing Antibacterial mAbs with Emerging Technologies

Recent advancements in cutting-edge technologies have significantly impacted the field of antibacterial mAbs, of-348 fering novel approaches to enhance their efficacy in combating bacterial infections. The integration of nanotechnology, 349 artificial intelligence (AI), and CRISPR-Cas gene-editing systems with mAb development and application has opened 350 up promising avenues for addressing the challenges posed by MDR bacterial pathogens. Nanotechnology has emerged 351 as a powerful tool for augmenting the therapeutic potential of antibacterial mAbs. Engineered nanoparticles serve as 352 effective carriers, facilitating targeted delivery of mAbs to infection sites and potentially improving their therapeutic 353 index [76]. Furthermore, nanoparticles functionalized with mAbs can act as 'molecular traps' for bacterial toxins or 354 whole bacteria, offering a novel approach to pathogen clearance [77]. The concept of theranostics, combining diagnostic 355 and therapeutic capabilities, has been realized through the integration of mAbs with nanoparticles, enabling simulta-356 neous detection and treatment of bacterial infections [78]. 357

The development of antibacterial mAbs is being revolutionized by AI and machine learning (ML). AI has signifi-358 cantly impacted antibody design through various approaches, with ML models now being used to optimize critical 359 antibody properties such as affinity, specificity, and developability (Makowski et al., 2022). These models can predict 360 antibody characteristics using sequences or structures, allowing for the early identification of promising candidates 361 (Kim et al., 2023b). Advanced AI-driven platforms have been developed to jointly generate antibody sequences and 362 structures while considering the target epitope, enabling more efficient and targeted antibody design (Akbar et al., 2022). 363 AI has also revolutionized the antibody discovery process by enabling the rapid production of antibodies through deep 364 generative models, generating large volumes of antigen-specific data efficiently and reducing reliance on traditional 365 experimental methods (Li et al., 2023). Moreover, AI has been instrumental in predicting immunogenicity, a crucial 366 aspect in evaluating the safety and efficacy of antibody therapeutics, by recognizing B and T cell epitopes that may 367 trigger an immunogenic response (Kim, et al., 2023b). The synergy between AI and other emerging technologies is 368 further amplifying the potential of antibacterial mAbs. The combination of AI with high-throughput screening technol-369 ogies and advanced structural biology techniques is enabling more rapid and accurate characterization of antibody-370 antigen interactions (Bennett et al., 2024). Additionally, the integration of AI with nanotechnology is opening new ave-371 nues for targeted delivery of antibacterial mAbs, potentially improving their efficacy against intracellular pathogens or 372 biofilm-associated bacteria. As AI and ML technologies continue to evolve, we can anticipate even more sophisticated 373 applications in antibacterial mAb development. Future directions may include AI-driven personalized antibody 374

therapies tailored to individual patient microbiomes and immune profiles, real-time adaptation of antibody designs in 375 response to emerging bacterial resistance patterns, and integration of AI with synthetic biology techniques for on-de-376 mand production of antibacterial mAbs. By enabling more efficient and targeted antibody development, optimizing 377 key properties, predicting immunogenicity, and streamlining the discovery process, these technologies are accelerating 378 our ability to combat multidrug-resistant bacterial infections (Makowski, et al., 2022). As these fields continue to ad-379 vance, we can expect increasingly sophisticated and effective antibacterial mAb therapies to emerge, offering new hope 380 in the fight against antibiotic-resistant pathogens. In the clinical domain, AI facilitates patient stratification and outcome 381 prediction in trials of antibacterial mAbs, potentially expediting the drug development process [80]. 382

The convergence of mAb technology with CRISPR-Cas gene-editing systems presents intriguing possibilities for 383 targeted bacterial therapeutics. mAbs could potentially serve as delivery vehicles for CRISPR-Cas systems, enabling 384 precise targeting of pathogenic bacteria. Furthermore, this combination might offer a means to reverse antibiotic re-385 sistance genes in bacteria, addressing one of the most pressing challenges in infectious disease management [81]. 386

These technological integrations collectively represent a paradigm shift in the approach to antibacterial mAb de-387 velopment and application. By leveraging nanotechnology, AI, and gene-editing technologies, researchers and clini-388 cians are poised to enhance the discovery, development, and therapeutic efficacy of mAbs in combating MDR bacterial 389 infections. This synergistic approach holds promise for overcoming current limitations and ushering in a new era of 390 targeted, effective antibacterial therapies. 391

#### Shortcomings and Future Prospects of Antibacterial Monoclonal Antibodies

The emergence of mAb-based immunotherapy as a potential solution to combat MDR bacterial infections has 393 sparked considerable interest in the medical community. However, this promising field faces several significant hurdles 394 that researchers must overcome to fully realize its therapeutic potential. One primary concern is the persistent risk of 395 HACA responses, even with the use of humanized mAbs. These responses can potentially compromise treatment effi-396 cacy and pose safety risks to patients (Mahdizade Ari et al., 2024). Another critical challenge lies in the highly specific 397 nature of mAb targets, which often correspond to antigens unique to particular bacterial species or strains. This speci-398 ficity necessitates rapid and precise pathogen identification to ensure appropriate mAb selection. Furthermore, the ex-399 pression of target antigens may be limited to specific bacterial strains, infection sites, or stages of disease progression, potentially restricting the efficacy of mAb therapies. A case in point is KB001-A, an antibody targeting the type 3 secretion system protein PcrV of Pseudomonas aeruginosa. While this mAb showed promise in reducing ventilator-associated 402 P. aeruginosa pneumonia, its efficacy was notably diminished in cystic fibrosis patients, highlighting the complexity of 403 translating laboratory success to diverse clinical scenarios(Cao et al., 2017). 404

The structural intricacies of bacterial cell surfaces present additional obstacles in mAb development. Many prom-405 ising targets, such as highly conserved outer membrane proteins, are often shielded by complex carbohydrate structures, 406 limiting antibody accessibility. This challenge is further compounded by the remarkable diversity of exopolysaccharide 407 structures among different bacterial serotypes. For instance, S. pneumoniae, a leading cause of pneumonia and meningi-408 tis, produces a protective capsule composed of variable exopolysaccharides crucial for its virulence and immune eva-409 sion strategies. The heterogeneity of these capsular structures across S. pneumoniae serotypes suggests that developing 410 a single mAb capable of broad-spectrum protection against this pathogen may be exceedingly difficult. However, some 411 researchers have focused on targeting more conserved bacterial structures. One such target is PNAG, an exopolysac-412 charide found in numerous pathogens and linked to their survival, toxicity, and biofilm formation capabilities. The 413 development of IgG1 mAb F598, which targets deacetylated synthetic PNAG, demonstrated promising results across 414 various microbial challenge models. Despite its potential, F598 did not progress beyond Phase 2 clinical trials, under-415 scoring the complex journey from preclinical promise to clinical success. Nevertheless, the insights gained from such 416 studies continue to inform future mAb development strategies. As the field advances, researchers are exploring inno-417 vative approaches to address these challenges, including the development of mAb cocktails targeting multiple epitopes, 418 the use of artificial intelligence in antibody design, and the integration of mAb therapies with traditional antibiotics to 419 enhance overall efficacy against MDR pathogens (Singh et al., 2018). 420

# Global Health Impact: Antibacterial mAbs in Diverse Healthcare Settings

Antibacterial mAbs have the potential to significantly impact healthcare in low- and middle-income countries by 422 providing targeted treatment options for bacterial infections, which are often prevalent in these regions (Wang-Lin and 423 Balthasar, 2018). The use of monoclonal antibodies as an antibacterial approach holds promise in addressing region-424 specific bacterial threats, offering a targeted and effective means to combat various pathogens (Zurawski and McLendon, 425

392

2020b). One of the key challenges in the global distribution and access to antibacterial mAbs lies in ensuring equitable 426 availability and affordability, especially in resource-limited settings. Overcoming logistical and financial barriers is cru-427 cial to ensure widespread access to these life-saving treatments (Johnson et al., 2023). Future directions in the field of 428 antibacterial mAbs may involve further research into novel antibody-peptide combinations for targeting specific bacte-429 rial strains, as well as exploring innovative strategies to enhance the efficacy and accessibility of these treatments glob-430 ally. Breakthroughs in antibody development and antimicrobial peptide fusion could pave the way for more effective 431 and accessible antibacterial therapies in diverse healthcare settings (Johnson, et al., 2023). Similar to the problems ob-432 served for vaccines and antibiotics, commercial investment tends to be influenced by market size of the disease. There-433 fore, the development of broad-spectrum mAbs needs to be guided by the policies of government regulators to reduce 434 commercial barriers and enable related fields to blossom. This remains an open question that requires addressing in the 435 foreseeable future. 436

#### Conclusion

The journey of mAbs in combating MDR bacterial infections stands at a critical juncture. As we've explored 438 throughout this review, the potential of mAbs to revolutionize our approach to treating resistant infections is substantial, yet not without challenges. The landscape of antibacterial mAbs is rapidly evolving. From the early days of mousederived antibodies to the current era of fully human and engineered antibodies, we've witnessed remarkable progress. 441 The success stories, such as bezlotoxumab for C. difficile infections, provide a glimpse of what's possible. However, the road ahead demands innovation, persistence, and a willingness to challenge conventional therapeutic paradigms. 443

One intriguing avenue for future research lies in the development of 'smart' mAbs capable of distinguishing be-444 tween commensal and pathogenic bacteria. Such precision could revolutionize treatment, minimizing disruption to the 445 beneficial microbiome while effectively targeting harmful pathogens. Imagine antibodies that not only neutralize bac-446 teria but also modulate the host immune response, enhancing natural defenses against infection. The potential synergy 447 between mAbs and other emerging technologies is another frontier ripe for exploration. Could we see nanoparticle-448 mAb conjugates that more effectively penetrate biofilms? Or mAbs engineered to carry CRISPR-Cas payloads, capable 449 of editing bacterial genomes to reverse antibiotic resistance? These may seem like science fiction today, but so did many 450 of our current medical marvels just a few decades ago. As we look to the future, the global health implications of mAb 451 therapies cannot be overstated. Their potential to address region-specific bacterial threats could transform healthcare 452 in resource-limited settings. However, realizing this potential will require overcoming significant hurdles in produc-453 tion, distribution, and affordability. Innovative approaches, such as plant-based antibody production or the develop-454 ment of thermostable formulations, could be game-changers in expanding access. The road ahead for antibacterial mAbs 455 is not without obstacles. Regulatory frameworks must evolve to keep pace with technological advancements. The eco-456 nomic realities of drug development continue to pose challenges, particularly for therapies targeting fewer common 457 pathogens. Collaboration between academia, industry, and government agencies will be crucial in overcoming these 458 hurdles. Moreover, as we delve deeper into the complexities of host-pathogen interactions, our understanding of how 459 to best deploy mAb therapies will undoubtedly evolve. Could personalized approaches, tailored to an individual's mi-460crobiome or immune profile, become the norm? Might we see combination therapies that pair mAbs with traditional 461 antibiotics or other novel antimicrobials, creating synergistic effects that overcome resistance mechanisms? 462

In conclusion, while the challenges are significant, the potential rewards of advancing mAb therapies for MDR 463 bacterial infections are immense. As researchers, clinicians, and policymakers, we stand at the threshold of a new era in 464 infectious disease treatment. By embracing innovation, fostering collaboration, and maintaining a patient-centered focus, we can work towards a future where MDR infections no longer pose the existential threat they do today. 466

The journey of antibacterial mAbs is far from over; in many ways, it's just beginning. As we move forward, let us approach this challenge with the urgency it demands, the creativity it requires, and the hope it inspires. The next chapter 468 in the story of antibacterial mAbs is ours to write, and its impact could reshape the landscape of global health for generations to come. 470

437



References	473
Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. 2012. scFv antibody: principles and clinical application. Clin Dev	474
Immunol 2012:980250.	475
Akbar R, Robert PA, Weber CR, Widrich M, Frank R, Pavlovic M, Scheffer L, Chernigovskaya M, Snapkov I, Slabodkin A, Mehta	476
BB, Miho E, Lund-Johansen F, Andersen JT, Hochreiter S, Hobaek Haff I, Klambauer G, Sandve GK, Greiff V. 2022. In silico proof	477
of principle of machine learning-based antibody design at unconstrained scale. MAbs 14:2031482.	478
Amro WA, Al-Qaisi W, Al-Razem F. 2018. Production and purification of IgY antibodies from chicken egg yolk. J Genet Eng	479
Biotechnol 16:99-103.	480
Anderson JDIV, Bagamian KH, Pecenka CJ, Muhib F, Puett CA, Hausdorff WP, Scheele S. 2023. Potential impact and cost-	481
effectiveness of <em>Shigella</em> vaccination in 102 low-income and middle-income countries in children aged 5 years or	482
younger: a modelling study. The Lancet Global Health 11:e880-e891.	483
Antimicrobial Resistance C. 2022. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet	484
Antinori A, Bausch-Jurken M. 2023. The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination	485
and Needs for the Future. J Infect Dis 228:S4-S12.	486
Bajema KL, Gierke R, Farley MM, Schaffner W, Thomas A, Reingold AL, Harrison LH, Lynfield R, Burzlaff KE, Petit S, Barnes M,	487
Torres S, Vagnone PMS, Beall B, Pilishvili T. 2022. Impact of Pneumococcal Conjugate Vaccines on Antibiotic-Nonsusceptible	488
Invasive Pneumococcal Disease in the United States. J Infect Dis 226:342-351.	489
Batchelder JI, Hare PJ, Mok WWK. 2023. Resistance-resistant antibacterial treatment strategies. Front Antibiot 2	490
Bennett NR, Watson JL, Ragotte RJ, Borst AJ, See DL, Weidle C, Biswas R, Shrock EL, Leung PJY, Huang B, Goreshnik I, Ault R,	491
Carr KD, Singer B, Criswell C, Vafeados D, Sanchez MG, Kim HM, Torres SV, Chan S, Baker D. 2024. Atomically accurate de novo	492
design of single-domain antibodies. bioRxiv	493
Buchy P, Ascioglu S, Buisson Y, Datta S, Nissen M, Tambyah PA, Vong S. 2020. Impact of vaccines on antimicrobial resistance. Int J	494
Infect Dis 90:188-196.	495
Buckley PT, Chan R, Fernandez J, Luo J, Lacey KA, DuMont AL, O'Malley A, Brezski RJ, Zheng S, Malia T, Whitaker B, Zwolak A,	496
Payne A, Clark D, Sigg M, Lacy ER, Kornilova A, Kwok D, McCarthy S, Wu B, Morrow B, Nemeth-Seay J, Petley T, Wu S, Strohl	497
WR, Lynch AS, Torres VJ. 2023. Multivalent human antibody-centyrin fusion protein to prevent and treat Staphylococcus aureus	498
infections. Cell Host Microbe 31:751-765 e711.	499
Butler MS, Henderson IR, Capon RJ, Blaskovich MAT. 2023. Antibiotics in the clinical pipeline as of December 2022. J Antibiot	500
(Tokyo) 76:431-473.	501
Cao J, Yi F, Tian Q, Dang G, Si W, Liu S, Yu S. 2017. Targeting the gram-negative bacteria peptidoglycan synthase MraY as a new	502
approach for monoclonal antibody anti-bacterial activity. Hum Vaccin Immunother 13:2086-2091.	503
Cassini A, Hogberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Colomb-Cotinat M, Kretzschmar ME,	504
Devleesschauwer B, Cecchini M, Ouakrim DA, Oliveira TC, Struelens MJ, Suetens C, Monnet DL, Burden of AMRCG. 2019.	505
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the	506
European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis 19:56-66.	507
Cavaco M, Castanho M, Neves V. 2022. The Use of Antibody-Antibiotic Conjugates to Fight Bacterial Infections. Front Microbiol	508
13:835677.	509
CDC. 2019. Antibiotic resistance threats in the United States 2019. US Centers for Disease Control and Prevention (CDC), Atlanta.	510
URL: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf [accessed 20 February 2019].	511
CDC. 2022. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. Atlanta, GA.	512
Chiang MH, Sung WC, Lien SP, Chen YZ, Lo AF, Huang JH, Kuo SC, Chong P. 2015. Identification of novel vaccine candidates	513
against Acinetobacter baumannii using reverse vaccinology. Hum Vaccin Immunother 11:1065-1073.	514

Chungyoun M, Gray JJ. 2023. AI Models for Protein Design are Driving Antibody Engineering. Curr Opin Biomed Eng 28	515
Davies NG, Flasche S, Jit M, Atkins KE. 2021. Modeling the effect of vaccination on selection for antibiotic resistance in	516
Streptococcus pneumonia e. Sci Transl Med 13	517
DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman	518
BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu X-Q, Suzich JA, Stover CK. 2014a. A multifunctional bispecific antibody	519
protects against <i>Pseudomonas aeruginosa</i> . Science Translational Medicine 6:262ra155-262ra155.	520
DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman	521
BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu XQ, Suzich JA, Stover CK. 2014b. A multifunctional bispecific antibody	522
protects against Pseudomonas aeruginosa. Sci Transl Med 6:262ra155.	523
Elemam NM, Ramakrishnan RK, Hundt JE, Halwani R, Maghazachi AA, Hamid Q. 2021. Innate Lymphoid Cells and Natural Killer	524
Cells in Bacterial Infections: Function, Dysregulation, and Therapeutic Targets. Front Cell Infect Microbiol 11:733564.	525
Frank DW, Vallis A, Wiener-Kronish JP, Roy-Burman A, Spack EG, Mullaney BP, Megdoud M, Marks JD, Fritz R, Sawa T. 2002.	526
Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 186:64-73.	527
Frost I, Sati H, Garcia-Vello P, Hasso-Agopsowicz M, Lienhardt C, Gigante V, Beyer P. 2023. The role of bacterial vaccines in the	528
fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline. Lancet Microbe 4:e113-e125.	529
Ghoneim HE, Thomas PG, McCullers JA. 2013. Depletion of alveolar macrophages during influenza infection facilitates bacterial	530
superinfections. J Immunol 191:1250-1259.	531
Gilchuk P, Murin CD, Milligan JC, Cross RW, Mire CE, Ilinykh PA, Huang K, Kuzmina N, Altman PX, Hui S, Gunn BM, Bryan AL,	532
Davidson E, Doranz BJ, Turner HL, Alkutkar T, Flinko R, Orlandi C, Carnahan R, Nargi R, Bombardi RG, Vodzak ME, Li S, Okoli	533
A, Ibeawuchi M, Ohiaeri B, Lewis GK, Alter G, Bukreyev A, Saphire EO, Geisbert TW, Ward AB, Crowe JE, Jr. 2020. Analysis of a	534
Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization. Immunity 52:388-403	535
e312.	536
Harding FA, Stickler MM, Razo J, DuBridge RB. 2010. The immunogenicity of humanized and fully human antibodies: residual	537
immunogenicity resides in the CDR regions. MAbs 2:256-265.	538
Huang W, Zhang Q, Li W, Chen Y, Shu C, Li Q, Zhou J, Ye C, Bai H, Sun W, Yang X, Ma Y. 2019. Anti-outer Membrane Vesicle	539
Antibodies Increase Antibiotic Sensitivity of Pan-Drug-Resistant Acinetobacter baumannii. Front Microbiol 10:1379.	540
Hwang WY, Foote J. 2005. Immunogenicity of engineered antibodies. Methods 36:3-10.	541
Jansen KU, Knirsch C, Anderson AS. 2018. The role of vaccines in preventing bacterial antimicrobial resistance. Nat Med 24:10-19.	542
Johnson K, Delaney JC, Guillard T, Reffuveille F, Varin-Simon J, Li K, Wollacott A, Frapy E, Mong S, Tissire H, Viswanathan K,	543
Touti F, Babcock GJ, Shriver Z, Pentelute BL, Plante O, Skurnik D. 2023. Development of an antibody fused with an antimicrobial	544
peptide targeting Pseudomonas aeruginosa: A new approach to prevent and treat bacterial infections. PLoS Pathog 19:e1011612.	545
Kang TH, Seong BL. 2020. Solubility, Stability, and Avidity of Recombinant Antibody Fragments Expressed in Microorganisms.	546
Front Microbiol 11:1927.	547
Kennedy DA, Read AF. 2017. Why does drug resistance readily evolve but vaccine resistance does not? Proc Biol Sci 284	548
Kim C, Holm M, Frost I, Hasso-Agopsowicz M, Abbas K. 2023a. Global and regional burden of attributable and associated bacterial	549
antimicrobial resistance avertable by vaccination: modelling study. BMJ Glob Health 8	550
Kim EG, Kim KM. 2015. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics.	551
Biomol Ther (Seoul) 23:493-509.	552
Kim J, McFee M, Fang Q, Abdin O, Kim PM. 2023b. Computational and artificial intelligence-based methods for antibody	553
development. Trends Pharmacol Sci 44:175-189.	554
Klemm J, Pekar L, Krah S, Zielonka S. 2021. Antibody Display Systems. In: Rüker F, Wozniak-Knopp G (Editors). Introduction to	555
Antibody Engineering. Cham: Springer International Publishing, p 65-96.	556

Langford BJ, So M, Raybardhan S, Leung V, Soucy JR, Westwood D, Daneman N, MacFadden DR. 2021. Antibiotic prescribing in	557
patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect 27:520-531.	558
Lee J-S, Mogasale V, Kim S, Cannon J, Giannini F, Abbas K, Excler J-L, Kim JH. 2023. The potential global cost-effectiveness of	559
prospective Strep A vaccines and associated implementation efforts. npj Vaccines 8:128.	560
Lee L, Samardzic K, Wallach M, Frumkin LR, Mochly-Rosen D. 2021. Immunoglobulin Y for Potential Diagnostic and Therapeutic	561
Applications in Infectious Diseases. Front Immunol 12	562
Lehar SM, Pillow T, Xu M, Staben L, Kajihara KK, Vandlen R, DePalatis L, Raab H, Hazenbos WL, Hiroshi Morisaki J, Kim J, Park	563
S, Darwish M, Lee B-C, Hernandez H, Loyet KM, Lupardus P, Fong R, Yan D, Chalouni C, Luis E, Khalfin Y, Plise E, Cheong J,	564
Lyssikatos JP, Strandh M, Koefoed K, Andersen PS, Flygare JA, Wah Tan M, Brown EJ, Mariathasan S. 2015. Novel antibody-	565
antibiotic conjugate eliminates intracellular S. aureus. Nature 527:323-328.	566
Li L, Gupta E, Spaeth J, Shing L, Jaimes R, Engelhart E, Lopez R, Caceres RS, Bepler T, Walsh ME. 2023. Machine learning	567
optimization of candidate antibody yields highly diverse sub-nanomolar affinity antibody libraries. Nat Commun 14:3454.	568
Little SF, Webster WM, Fisher DE. 2011. Monoclonal antibodies directed against protective antigen of Bacillus anthracis enhance	569
lethal toxin activity in vivo. FEMS Immunol Med Microbiol 62:11-22.	570
López-Siles M, Corral-Lugo A, McConnell MJ. 2020. Vaccines for multidrug resistant Gram negative bacteria: lessons from the past	571
for guiding future success. FEMS Microbiol Rev 45:fuaa054.	572
Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC. 2020. Development of therapeutic antibodies for the treatment of	573
diseases. J Biomed Sci 27:1.	574
Mahdizade Ari M, Amini ME, Sholeh M, Zahedi Bialvaei A. 2024. The effect of polyclonal and monoclonal based antibodies as	575
promising potential therapy for treatment of sepsis: A systematic review. New Microbes New Infect 60-61:101435.	576
Mak IW, Evaniew N, Ghert M. 2014. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res	577
6:114-118.	578
Makowski EK, Kinnunen PC, Huang J, Wu L, Smith MD, Wang T, Desai AA, Streu CN, Zhang Y, Zupancic JM, Schardt JS,	579
Linderman JJ, Tessier PM. 2022. Co-optimization of therapeutic antibody affinity and specificity using machine learning models	580
that generalize to novel mutational space. Nat Commun 13:3788.	581
Mariathasan S, Tan MW. 2017. Antibody-Antibiotic Conjugates: A Novel Therapeutic Platform against Bacterial Infections. Trends	582
Mol Med 23:135-149.	583
Maynard AWNaJA. 2021. Protein Engineering: Tools and Applications. WILEY-VCH GmbH. 317-351 p.	584
McConnell MJ. 2019. Where are we with monoclonal antibodies for multidrug-resistant infections? Drug Discov Today 24:1132-	585
1138.	586
McCulloch TR, Wells TJ, Souza-Fonseca-Guimaraes F. 2022. Towards efficient immunotherapy for bacterial infection. Trends	587
Microbiol 30:158-169.	588
Medicine UNLo. 2023. ClinicalTrials.gov. URL: <u>https://clinicaltrials.gov</u> [accessed August 7 2023].	589
Mei Y, Chen Y, Sivaccumar JP, An Z, Xia N, Luo W. 2022. Research progress and applications of nanobody in human infectious	590
diseases. Front Pharmacol 13:963978.	591
Michalik M, Djahanshiri B, Leo JC, Linke D. 2016. Reverse Vaccinology: The Pathway from Genomes and Epitope Predictions to	592
Tailored Recombinant Vaccines. Methods Mol Biol 1403:87-106.	593
Monserrat-Martinez A, Gambin Y, Sierecki E. 2019. Thinking Outside the Bug: Molecular Targets and Strategies to Overcome	594
Antibiotic Resistance. Int J Mol Sci 20	595
Motley MP, Banerjee K, Fries BC. 2019. Monoclonal antibody-based therapies for bacterial infections. Curr Opin Infect Dis 32:210-	596
216.	597

Muñoz-López P, Ribas-Aparicio RM, Becerra-Báez EI, Fraga-Pérez K, Flores-Martínez LF, Mateos-Chávez AA, Luria-Pérez R. 2022.	598
Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy. Cancers (Basel) 14	599
Nyakatura EK, Soare AY, Lai JR. 2017. Bispecific antibodies for viral immunotherapy. Hum Vaccin Immunother 13:836-842.	600
O'Neill J. 2014. Review on Antimicrobial Resistance Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations.	601
London.	602
Orth P, Xiao L, Hernandez LD, Reichert P, Sheth PR, Beaumont M, Yang X, Murgolo N, Ermakov G, DiNunzio E, Racine F,	603
Karczewski J, Secore S, Ingram RN, Mayhood T, Strickland C, Therien AG. 2014. Mechanism of action and epitopes of Clostridium	604
difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography. J Biol Chem 289:18008-18021.	605
Pasero D, Cossu AP, Terragni P. 2021. Multi-Drug Resistance Bacterial Infections in Critically Ill Patients Admitted with COVID-19.	606
Microorganisms 9	607
Pietrzykowski M, Flanagan W, Pizzi V, Brown A, Sinclair A, Monge M. 2013. An environmental life cycle assessment comparison	608
of single-use and conventional process technology for the production of monoclonal antibodies. Journal of Cleaner Production	609
41:150-162.	610
Raafat D, Otto M, Reppschlager K, Iqbal J, Holtfreter S. 2019. Fighting Staphylococcus aureus Biofilms with Monoclonal	611
Antibodies. Trends Microbiol 27:303-322.	612
Ryser S, Tenorio E, Estelles A, Kauvar LM. 2019. Human antibody repertoire frequently includes antibodies to a bacterial biofilm	613
associated protein. PLoS One 14:e0219256.	614
Saha SK, Tabassum N, Saha S. 2021. Typhoid Conjugate Vaccine: An Urgent Tool to Combat Typhoid and Tackle Antimicrobial	615
Resistance. The Journal of Infectious Diseases 224:S788-S791.	616
Salvador JP, Vilaplana L, Marco MP. 2019. Nanobody: outstanding features for diagnostic and therapeutic applications. Anal	617
Bioanal Chem 411:1703-1713.	618
Satheeshkumar PK. 2020. Expression of Single Chain Variable Fragment (scFv) Molecules in Plants: A Comprehensive Update. Mol	619
Biotechnol 62:151-167.	620
Sedykh SE, Prinz VV, Buneva VN, Nevinsky GA. 2018. Bispecific antibodies: design, therapy, perspectives. Drug Design,	621
Development and Therapy 12:195-208.	622
Seixas AMM, Sousa SA, Leitao JH. 2022. Antibody-Based Immunotherapies as a Tool for Tackling Multidrug-Resistant Bacterial	623
Infections. Vaccines (Basel) 10	624
Singh S, Kumar NK, Dwiwedi P, Charan J, Kaur R, Sidhu P, Chugh VK. 2018. Monoclonal Antibodies: A Review. Curr Clin	625
Pharmacol 13:85-99.	626
Soliman C, Pier GB, Ramsland PA. 2020. Antibody recognition of bacterial surfaces and extracellular polysaccharides. Curr Opin	627
Struct Biol 62:48-55.	628
Stokes JM, Lopatkin AJ, Lobritz MA, Collins JJ. 2019. Bacterial Metabolism and Antibiotic Efficacy. Cell Metab 30:251-259.	629
Szijártó V, Nagy E, Nagy G. 2018. Directly Bactericidal Anti- <em>Escherichia coli</em> Antibody. Trends in Microbiology 26:642-	630
644.	631
Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A, Holz FG. 2021. Brolucizumab: A Newly Developed Anti-VEGF	632
Molecule for the Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmologica 244:93-101.	633
Thomsen K, Christophersen L, Bjarnsholt T, Jensen PO, Moser C, Hoiby N. 2016a. Anti-Pseudomonas aeruginosa IgY antibodies	634
augment bacterial clearance in a murine pneumonia model. J Cyst Fibros 15:171-178.	635
Thomsen K, Christophersen L, Bjarnsholt T, Jensen PØ, Moser C, Høiby N. 2016b. Anti-Pseudomonas aeruginosa IgY antibodies	636
augment bacterial clearance in a murine pneumonia model. Journal of Cystic Fibrosis 15:171-178.	637

Tvilum A, Johansen MI, Glud LN, Ivarsen DM, Khamas AB, Carmali S, Mhatre SS, Sogaard AB, Faddy E, de Vor L, Rooijakkers	638
SHM, Ostergaard L, Jorgensen NP, Meyer RL, Zelikin AN. 2023. Antibody-Drug Conjugates to Treat Bacterial Biofilms via	639
Targeting and Extracellular Drug Release. Adv Sci (Weinh) 10:e2301340.	640
Vacca F, Sala C, Rappuoli R. 2022. Monoclonal Antibodies for Bacterial Pathogens: Mechanisms of Action and Engineering	641
Approaches for Enhanced Effector Functions. Biomedicines 10	642
Wang-Lin SX, Balthasar JP. 2018. Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in	643
the Treatment of Bacterial Infections. Antibodies (Basel) 7	644
Wang H, Chen D, Lu H. 2022. Anti-bacterial monoclonal antibodies: next generation therapy against superbugs. Applied	645
Microbiology and Biotechnology 106:3957-3972.	646
Warrener P, Varkey R, Bonnell JC, DiGiandomenico A, Camara M, Cook K, Peng L, Zha J, Chowdury P, Sellman B, Stover CK.	647
2014. A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection	648
models. Antimicrob Agents Chemother 58:4384-4391.	649
Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim	650
YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB, Modify I, Investigators MI. 2017.	651
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med 376:305-317.	652
Yadav PD, Mendiratta SK, Mohandas S, Singh AK, Abraham P, Shete A, Bandyopadhyay S, Kumar S, Parikh A, Kalita P, Sharma	653
V, Pandya H, Patel CG, Patel M, Soni S, Giri S, Jain M. 2021. ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in	654
Syrian Hamsters against SARS-CoV-2 Infection. Viruses 13	655
Yang Y, Qian M, Yi S, Liu S, Li B, Yu R, Guo Q, Zhang X, Yu C, Li J, Xu J, Chen W. 2016. Monoclonal Antibody Targeting	656
Staphylococcus aureus Surface Protein A (SasA) Protect Against Staphylococcus aureus Sepsis and Peritonitis in Mice. PLoS One	657
11:e0149460.	658
Zhen YH, Jin LJ, Guo J, Li XY, Li Z, Fang R, Xu YP. 2008. Characterization of specific egg yolk immunoglobulin (IgY) against	659
mastitis-causing Staphylococcus aureus. J Appl Microbiol 105:1529-1535.	660
Zhou C, Lehar S, Gutierrez J, Rosenberger CM, Ljumanovic N, Dinoso J, Koppada N, Hong K, Baruch A, Carrasco-Triguero M,	661
Saad O, Mariathasan S, Kamath AV. 2016. Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB <sup>TM</sup>	662
antibody antibiotic conjugate against Staphylococcus aureus in mice. MAbs 8:1612-1619.	663
Zurawski DV, McLendon MK. 2020a. Monoclonal antibodies as an antibacterial approach against bacterial pathogens. Antibiotics	664
9:155.	665
Zurawski DV, McLendon MK. 2020b. Monoclonal Antibodies as an Antibacterial Approach Against Bacterial Pathogens.	666
Antibiotics (Basel) 9	667
	668